AU2017302330A1 - Combination therapies for treating cancer - Google Patents

Combination therapies for treating cancer Download PDF

Info

Publication number
AU2017302330A1
AU2017302330A1 AU2017302330A AU2017302330A AU2017302330A1 AU 2017302330 A1 AU2017302330 A1 AU 2017302330A1 AU 2017302330 A AU2017302330 A AU 2017302330A AU 2017302330 A AU2017302330 A AU 2017302330A AU 2017302330 A1 AU2017302330 A1 AU 2017302330A1
Authority
AU
Australia
Prior art keywords
compound
formula
chemotherapeutic agent
doxorubicin
leukemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2017302330A
Other languages
English (en)
Inventor
John H. Bushweller
Anuradha Illendula
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UVA Licensing and Ventures Group
Original Assignee
University of Virginia Patent Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Virginia Patent Foundation filed Critical University of Virginia Patent Foundation
Publication of AU2017302330A1 publication Critical patent/AU2017302330A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AU2017302330A 2016-07-27 2017-07-27 Combination therapies for treating cancer Abandoned AU2017302330A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662367263P 2016-07-27 2016-07-27
US62/367,263 2016-07-27
PCT/US2017/044124 WO2018022855A1 (en) 2016-07-27 2017-07-27 Combination therapies for treating cancer

Publications (1)

Publication Number Publication Date
AU2017302330A1 true AU2017302330A1 (en) 2019-01-17

Family

ID=61016782

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017302330A Abandoned AU2017302330A1 (en) 2016-07-27 2017-07-27 Combination therapies for treating cancer

Country Status (13)

Country Link
US (1) US11241421B2 (https=)
EP (1) EP3490557B1 (https=)
JP (1) JP2019525924A (https=)
KR (1) KR20190032370A (https=)
CN (1) CN109475542A (https=)
AU (1) AU2017302330A1 (https=)
BR (1) BR112019000049A2 (https=)
CA (1) CA3028461A1 (https=)
EA (1) EA201990395A1 (https=)
IL (1) IL263942A (https=)
MX (1) MX2019000179A (https=)
WO (1) WO2018022855A1 (https=)
ZA (1) ZA201900438B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021525280A (ja) 2018-05-24 2021-09-24 ユニバーシティ オブ バージニア パテント ファウンデーション がんを治療するための併用療法
CN117567434A (zh) * 2022-08-08 2024-02-20 武汉大学 靶向CBFβ-SMMHC蛋白的PROTAC类化合物及其制备方法与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643935A (en) 1995-06-07 1997-07-01 The University Of North Carolina At Chapel Hill Method of combatting infectious diseases using dicationic bis-benzimidazoles
US6372719B1 (en) * 1998-03-04 2002-04-16 Jay Cunningham ανβ3 integrin antagonists in combination with chemotherapeutic agents
WO2006104668A2 (en) 2005-03-11 2006-10-05 Temple University - Of The Commonwealth System Of Higher Education Composition and methods for the treatment of proliferative diseases
CA2614324A1 (en) * 2005-07-06 2007-01-18 Kanisa Pharmaceuticals, Inc. Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
EP3670509B1 (en) * 2009-05-13 2023-04-19 University of Virginia Patent Foundation Inhibitors of inv(16) leukemia

Also Published As

Publication number Publication date
CN109475542A (zh) 2019-03-15
MX2019000179A (es) 2019-06-20
ZA201900438B (en) 2019-10-30
JP2019525924A (ja) 2019-09-12
EP3490557A1 (en) 2019-06-05
US11241421B2 (en) 2022-02-08
CA3028461A1 (en) 2018-02-01
KR20190032370A (ko) 2019-03-27
US20190343820A1 (en) 2019-11-14
IL263942A (en) 2019-02-28
EA201990395A1 (ru) 2019-07-31
WO2018022855A1 (en) 2018-02-01
EP3490557B1 (en) 2022-09-07
EP3490557A4 (en) 2020-04-01
BR112019000049A2 (pt) 2019-04-02

Similar Documents

Publication Publication Date Title
ES2811367T3 (es) Análogos de éteres fosfolipídicos como vehículos de fármacos que seleccionan como objetivo el cáncer
US11446309B2 (en) Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors
CN105873440B (zh) 抑制tie2激酶的组合物在制备治疗癌症的药物中的用途
JP2024166290A (ja) 血液癌の併用療法
SG11202111402PA (en) Anti-cancer nuclear hormone receptor-targeting compounds
JP7434185B2 (ja) 三置換ベンゾトリアゾール誘導体の使用方法
JP2019069969A (ja) 骨髄異形成症候群を治療するためのタンパク質ホスファターゼ２ａ阻害剤
TW201006823A (en) Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis
KR102336767B1 (ko) 골수증식성 신생물 및 만성 골수성 백혈병을 포함하는, 트랜스듀신 β―유사 단백질 １（ＴＢＬ １） 활성과 관련된 질환 또는 장애의 치료 방법
EP3490557B1 (en) Combination therapies for treating cancer
KR101930859B1 (ko) 피라지노-트리아진 유도체를 포함하는 비소세포성폐암 예방 및 치료용 조성물
JP2026012832A (ja) 腫瘍治療用医薬組成物
TWI753178B (zh) Mcl-1抑制劑與血液癌症標準療法之組合，其用途及醫藥組合物
WO2014047782A1 (zh) 含有白藜芦醇及白藜芦醇类衍生物和Bcl-2抑制剂的药物组合物及其应用
CA2398643A1 (en) Novel compounds
JP2020023447A (ja) フェニルテトラヒドロピリドインドール誘導体及び医薬組成物
HK40003583A (en) Combination therapies for treating cancer
WO2020242910A1 (en) Compositions and methods for treating cancer
CN102083436A (zh) 抗肿瘤组合物和方法
US20110172184A1 (en) Antitumor agent containing 4 - [[3,5 - bis (trimethylsilyl) benzoyl] amino] benzoic acid
WO2022216930A1 (en) Novel mda-9 antagonist with anti-metastatic potential
WO2025174879A1 (en) Methods of reducing or eliminating measurable residual disease
AU2024351866A1 (en) Novel combination therapy for blood cancer
KR20230142733A (ko) 암 치료용 조성물 및 방법
GB2504550A (en) Diarylurea compound PQ401 for inhibiting the growth and/or proliferation of cancer stem cells

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application